Chronix Biomedical, Inc., a developer of novel blood-based cancer molecular diagnostics, is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting. The abstract will be released on 17 May, ahead of the conference which takes place on 2-6 June, 2017.

The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI)-score as a prognostic test in head and neck cancer. The study compares the Chronix CNI-score test’s accuracy as a predictor of time to progression with the current method based on clinical parameters (e.g. staging, invasion of lymph nodes). Predicted time to progression is an important factor that that can aid the therapeutic decision (i.e. adjuvant treatment) in this condition.

CHRONIX BIOMEDICAL, INC

Chronix Biomedical, Inc. is a molecular diagnostics company offering laboratory developed blood tests to doctors for cancer screening supplemental evaluations and monitoring cancer through its own certified laboratories. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany. Currently, Chronix Biomedical is offering 4 different tests.

stethoscope

CNI Monitor

A blood test that indicates whether a treatment is working in one to two cycles of therapy with over 90% positive predictive value.

microscope

CNI Screen

A blood test that reveals mutations mostly seen in patients with cancer.

heart

CNI Second Opinion™ prostate cancer evaluation test

A blood test for men with elevated PSA that reveals the mutations mostly seen in patients with prostate cancer.

blood

CNI Second Opinion™ breast cancer evaluation test

A blood test for patients with abnormal mammograms or lumps that reveals the mutations mostly seen in patients with breast cancer.

CHRONIX NEWS

  • Chronix Biomedical, liquid biopsy

Chronix notes abstract disclosure for forthcoming ASCO presentation. Head and neck cancer study finds CNI score to be a stronger predictor of time to recurrence than current method based on lymph node invasion.

The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer.

It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status).

  • Chronix Biomedical

Chronix Biomedical is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the ASCO Annual Meeting.

Chronix Biomedical

The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI) score as a prognostic test in head and neck cancer.

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

Chronix Biomedical

First study of a liquid biopsy to predict response to immunotherapy...

VIDEOS

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Lecture at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

Chronix Biomedical – Our Technology

#TheTurningPointInCancerFight

Paul Freiman, Chairman, Chronix – about CNI Tests

#TheTurningPointInCancerFight

ORDER TESTS

Go to Modern Cancer Diagnostics or Advanced Cancer Diagnostics to order our tests

EVENTS

  • laboratory2

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: [...]

  • ASCO-2016

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented [...]

PUBLICATIONS

  • Chronix Biomedical, liquid biopsy

Chronix notes abstract disclosure for forthcoming ASCO presentation. Head and neck cancer study finds CNI score to be a stronger predictor of time to recurrence than current method based on lymph node invasion.

The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer.

It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status).

  • Chronix Biomedical

Cohort Study in LiverTx

Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286

Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.

  • liquid biopsy - Chronix Biomedical

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

DOCTORS ABOUT OUR TESTS

“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”
Howard Urnovitz, CEO of Chronix Biomedical